Shanghai Nianxing Industrial Co., Ltd
China
Product Name: Palmitic acid
Price: Check
Purity: 98.0%
Stocking Period: 10 Day
Contact: Yang
Email: sales@echemcloud.com

2412195-89-0

2412195-89-0 structure

2412195-89-0 structure

Name: PI3Kδ/γ-IN-2
Chemical Name: PI3Kδ/γ-IN-2
CAS Number: 2412195-89-0
Molecular Formula: C₂₅H₂₁ClN₈O
Molecular Weight: 484.94
Catalog: Signaling Pathways PI3K/Akt/mTOR PI3K
Create Date: 2022-07-04 10:20:00
Modify Date: 2024-01-07 18:24:18
PI3Kδ/γ-IN-2 is a potent PI3Kδ and PI3Kγ dual inhibitor with IC50s of 1 nM and 4.3 nM, respectively. PI3Kδ/γ-IN-2 has favorable oral bioavailability. PI3Kδ/γ-IN-2 has potential for battling B-cell malignancies[1].

Name	PI3Kδ/γ-IN-2

Description	PI3Kδ/γ-IN-2 is a potent PI3Kδ and PI3Kγ dual inhibitor with IC50s of 1 nM and 4.3 nM, respectively. PI3Kδ/γ-IN-2 has favorable oral bioavailability. PI3Kδ/γ-IN-2 has potential for battling B-cell malignancies[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> PI3K/Akt/mTOR >> PI3K
Target	PI3Kδ:1 nM (IC50) PI3Kγ:4.3 nM (IC50)
In Vitro	PI3Kδ/γ-IN-2 (compound 26) (0-5 μM; 72 hours) exhibits remarkable anti-proliferative activity against SU-DHL-6 cell line[1]. PI3Kδ/γ-IN-2 (10-100 nM; 2 hours) down-regulates both phos-Akt (Ser473) and phos-S6K1 (Thr389), and decreases the phosphoration of Akt and S6K1 at 30 nM[1]. Cell Proliferation Assay Cell Line: SU-DHL-6[1] Concentration: 0-5 μM Incubation Time: 72 hours Result: Exhibited remarkable anti-proliferative activity against SU-DHL-6 cell line with GI50 value of 33 nM. Western Blot Analysis Cell Line: SU-DHL-6[1] Concentration: 10, 30 and 100 nM Incubation Time: 2 hours Result: Down-regulated both phos-Akt (Ser473) and phos-S6K1 (Thr389) in a dose-dependent manner, and exhibited a more significant decrease in the phosphoration of Akt and S6K1 at 30 nM.
In Vivo	PI3Kδ/γ-IN-2 (5 mg/kg; PO or IV; single) exhibits a high plasma exposure, an attractive oral bioavailability, and an acceptable clearance[1]. Pharmacokinetic Parameters of PI3Kδ/γ-IN-2 in male Sprague-Dawley rats[1]. IV (5 mg/kg) PO (5 mg/kg) T1/2 (h) 3.0 ± 0.3 14.3 ± 4.4 AUC0-t (h·μg/L) 5576 ± 606 4878 ± 694 VSS (L/kg) 3.9 ± 0.6 CL (L/h/kg) 0.9 ± 0.1 F (%) 87.5 ± 12.5 Animal Model: Male Sprague-Dawley rats[1] Dosage: 5 mg/kg Administration: PO or IV; single (Pharmacokinetics Analysis) Result: Exhibited a high plasma exposure (AUC0-t = 4878 ± 694 h μg/L), an attractive oral bioavailability (F% = 87.5 ± 12.5), and an acceptable clearance (CL = 0.9 ± 0.1 L/h/kg).
References	[1]. Tao Q, et al. Structurally novel PI3Kδ/γ dual inhibitors characterized by a seven-membered spirocyclic spacer: The SARs investigation and PK evaluation. Eur J Med Chem. 2020;191:112143.

Molecular Formula	C₂₅H₂₁ClN₈O
Molecular Weight	484.94

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.